Post-earnings recap
Reported
Tue, Aug 4, 2026
EPS actual
$0.77
EPS est.
$0.68
EPS surprise
+13.91%
1-day move
+1.52%
Pfizer's earnings report showed a strong performance in EPS, exceeding expectations by nearly 14%. However, revenue figures were not disclosed, which leaves some uncertainty. The stock reacted positively, rising by 1.52%, likely reflecting investor confidence in the EPS performance despite the lack of revenue details.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.77 | $0.68 | +13.91% |
| Revenue | N/A | $14.4B | N/A |
No transcript is on record, so the analysis is based solely on numerical results.
Pfizer Inc. is a leading pharmaceutical company known for its innovative medicines and vaccines. Operating in the Health Care sector, Pfizer plays a crucial role in addressing global health challenges, including infectious diseases and chronic conditions.
Last quarter
In Q1 2026, Pfizer reported an EPS of $0.75, exceeding expectations by 5.63%. The stock reacted positively, gaining 0.57% the following day.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+30.82%
Avg 1-day reaction
+0.38%
Analysts are cautiously optimistic about Pfizer's upcoming earnings, expecting it to meet or slightly exceed EPS and revenue estimates.
Bull case
If Pfizer beats expectations, it could signal strong demand for its products and a robust pipeline, potentially boosting investor confidence.
Bear case
Conversely, if the company fails to meet estimates, it may raise concerns about sales growth and market competition.
Key metrics to watch
EPS
$0.68Earnings per share is a key indicator of profitability and helps gauge the company's financial health.
Revenue
$14.4BRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will EPS exceed the consensus estimate of $0.68?
A beat on EPS could reinforce confidence in Pfizer's profitability and growth trajectory.
Q2
What are the revenue projections for key products?
Understanding revenue from major products will provide insights into market demand and future growth potential.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The consensus may underestimate Pfizer's ability to capitalize on its recent product launches, particularly in the vaccine market.
Supporting evidence
Recent product innovations could drive higher-than-expected sales.
Options pricing suggests a larger move than historical averages, indicating potential volatility.
Pfizer's strong track record of beating EPS estimates may not be fully appreciated.
Key risk
If key product revenues significantly exceed expectations, it could challenge the current consensus outlook.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it reflects the company's ability to navigate a competitive pharmaceutical landscape.
Bull confirmed if
A revenue figure above $14.6B would confirm the bull case, indicating strong product demand.
Bear confirmed if
Revenue below $14.0B would support the bear case, raising concerns about sales growth.
What the market is pricing for the move.
Implied Move
±9.1%
Historical Avg
±2.2%
The options market is pricing in a significant move, indicating uncertainty or anticipation surrounding the earnings report.
Options are pricing ±9.1% while PFE has averaged ±2.2% over the last 8 prints — setup is pricing rich.
ATM IV
0.2%
30d HV
16.8%
Smart-money positioning from the most recent 13F filings.
Institutional
69.16%
of float
Insider
0.10%
of float
Holders
3,618
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
529,670,433 sh · $14.8B
9.29%
6.3%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Pfizer beats expectations, history suggests a potential stock increase of around 0.46%, confirming positive market sentiment.
In line / cautious
An in-line result may lead to muted reactions as investors await further commentary on future growth.
Miss
Should Pfizer miss expectations, the stock could decline, with historical patterns suggesting a potential drop of around 0.46%.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
0 buys·1 sell
Members
1
Senate only
Est. Notional
$15,001.00–$50,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Vanguard Capital Management LLC
372,149,852 sh · $10.4B
6.53%
0.7%
State Street Corporation
307,090,897 sh · $8.6B
5.39%
1.8%
Geode Capital Management, LLC
135,275,782 sh · $3.8B
2.37%
1.3%
Vanguard Portfolio Management LLC
119,235,030 sh · $3.3B
2.09%
2.1%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
Recent Transactions
Traded Jun 8, 2026 · disclosed Jul 16, 2026
$15,001.00–$50,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.